SSG
NRIX icon

Summit Securities Group’s Nurix Therapeutics NRIX Stock Holding History

Summit Securities Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-779
Closed -$12.1K – 1307
2026
Q1 		$12.1K Buy
+779
New +$12.9K ﹤0.01% 630
2025
Q2 		– Sell
-155
Closed -$1.84K – 1313
2025
Q1 		$1.84K Buy
+155
New +$2.59K ﹤0.01% 674

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Summit Securities Group's NRIX Position: Q2 2026 in Review

Summit Securities Group sold out of Nurix Therapeutics (NRIX) in Q2 2026, closing a stake of 779 shares — an estimated $12.1K sold.

Summit Securities Group first reported a position in NRIX in Q1 2025 and held it in 2 quarters. The position peaked at $12.1K in Q1 2026. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Summit Securities Group reported no remaining Nurix Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Summit Securities Group sold 779 Nurix Therapeutics shares in Q2 2026, an estimated $12.1K.
  • Summit Securities Group first reported a position in Nurix Therapeutics in Q1 2025 and held it in 2 quarters.
  • Summit Securities Group's Nurix Therapeutics position peaked at $12.1K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.